news
Genetic fault reduces the effectiveness of leukaemia treatment
A genetic fault has been identified in people with an aggressive type of leukaemia that can significantly affect how they respond to treatment...
List view / Grid view
Acute myeloid leukaemia (AML)
news
FDA approves Mylotarg for treatment of acute myeloid leukemia
The FDA has approved Mylotarg for the treatment of adults with newly diagnosed acute myeloid leukaemia whose tumours express the CD33 antigen...
news
FDA approves new targeted treatment for acute myeloid leukemia
The U.S. Food and Drug Administration has granted the approval of Idhifa to Celgene Corporation and RealTime IDH2 Assay to Abbott Laboratories...
news
FDA approves new combination treatment for acute myeloid leukaemia
4 May 2017 | By Niamh Marriott, Junior Editor
The drug is approved for use in combination with LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML...
news
Bellicum recommended for $16.9 million Texan cancer research award
22 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The Institute of Texas award would fund a 3 year global clinical program of clinical trials for adult and paediatric patients acute myeloid leukaemia...
news
Novartis’ acute myeloid leukaemia drug granted FDA priority review
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA granted priority review to the PKC412 (midostaurin) new drug application as treatment for acute myeloid leukaemia...
news
Immune receives FDA guidance for acute myeloid leukaemia Phase III trial
28 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The proposed phase III study design reviewed by the FDA guidance focuses on overall survival as the primary endpoint, including Leukaemia Free Survival...
news
Daiichi Sankyo enrols first patient in Phase III acute myeloid leukaemia trial
17 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Daiichi Sankyo has enrolled their first patient in the global phase 3 QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients...
news
Jazz Pharmaceuticals seeks FDA drug application approval for leukaemia treatment
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The company expects to complete the submission of the new drug application (NDA) for vyxeos by early 2017, and will request a priority review...
news
Pluristem contracts CRO for Phase I trial of PLX-R18
12 July 2016 | By Victoria White, Digital Content Producer
The Phase I trial will evaluate the safety of intramuscular injections of PLX-R18 cells in 30 patients with incomplete haematopoietic recovery...
news
First patient treated in fourth dose level NKR-2 Phase I/IIa trial
23 June 2016 | By Victoria White, Digital Content Producer
The study is evaluating Celyad's NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma...
news
Safety follow-up completed for third dose level of NKR-2 trial
26 May 2016 | By Victoria White, Digital Content Producer
Celyad has completed the safety follow-up of the third dose level cohort in its Phase I/IIa clinical trial of its NKR-2 T-cell therapy...
news
Positive interim review in ongoing AML WT1 T cell clinical trial
14 April 2016 | By Victoria White, Digital Content Producer
The Cell and Gene Therapy Catapult has announced a positive interim review of a Phase I/II trial using WT1-TCR t-cell therapy to target acute myeloid leukaemia...
news
FDA grants orphan drug designation to Iomab-B
31 March 2016 | By Victoria White
Actinium’s Iomab-B is a radioimmunotherapeutic that conditions relapsed and refractory AML patients for a haematopoietic stem cell transplant...
news
Celyad posts an update on its NKR-2 Trial
30 March 2016 | By Victoria White
Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy...
